

General Information

| | |
|----------------------------|---|
| Synonyms | Beta-2-glycoprotein 1, B2GPI, APOH, |
| Accession # | P02749 |
| Source | Human embryonic kidney cell, HEK293-derived human Apolipoprotein H-domain 1 protein |
| | Gly20-Arg82 |
| Predicted Molecular weight | 7.1 kDa |

Components and Storage

| | |
|-------------|--|
| Formulation | Solution protein. |
| | Dissolved in PBS buffer to a concentration of 1.0 mg/mL. |
| | This solution can be diluted into other aqueous buffers. Centrifuge the vial prior to opening. |


| | |
|-----------------------|--|
| Storage and Stability | Avoid repeated freeze-thaw cycles. |
| | It is recommended that the protein be aliquoted for optimal storage. |
| | 12 months from date of receipt, -20 to -70 °C as supplied. |

| | |
|----------|------------------------|
| Shipping | Shipping with dry ice. |
|----------|------------------------|

Quality


| | |
|-----------------|--|
| Purity | > 95%, determined by SDS-PAGE. |
| Endotoxin Level | <0.010 EU per 1 ug of the protein by the LAL method. |
| Activity | Testing in progress. |

SDS-PAGE



4 ug/lane protein was resolved with SDS-PAGE under non-reducing (NR) and reducing (R) conditions and visualized by Coomassie Blue staining.

Gel filtration



Size-exclusion chromatography of recombinant human APOH (Domain 1) protein (280 nm absorbance)

Background

Apolipoprotein H (ApoH), also known as beta 2-Glycoprotein I/ beta 2-GPI, activated protein C-binding protein, B2GPI, and B2G1, is a 50 kDa variably glycosylated member of the complement control superfamily of proteins (1, 2). Mature human ApoH shares 76% and 82% aa sequence identity with mouse and rat ApoH, respectively. Hepatocyte-derived ApoH binds directly to negatively charged phospholipids (3). It circulates as a component of lipoprotein particles and as a lipid-free serum protein (4). Circulating levels of ApoH are positively correlated with triglyceride-rich lipoprotein (VLDL) components in type II diabetes (5). ApoH inhibits thrombosis by blocking the activation of Coagulation Factor XI but also shows procoagulant activity by inhibiting the activation of Protein C (6, 7). ApoH can be cleaved by Plasmin at Lys317 – Thr318, an action that is enhanced by heparin (8, 9). ApoH cleavage reduces its ability to bind phospholipids and inhibit Factor XI activation but confers the ability to bind Plasminogen (6, 8, 10). Cleaved ApoH also demonstrates antiangiogenic activity, whereas intact ApoH does not (14). The production of antibodies against ApoH is a hallmark of Antiphospholipid Syndrome (APS), an autoimmune disorder that leads to hypercoagulability and recurrent miscarriages (11). ApoH binds to the surface antigen of Hepatitis B Virus and is associated with the development of HBV-induced hepatocellular carcinoma (4, 12).

Reference

| | |
|--|--|
| 1. Crook, M.A. et al. (2010) <i>Atherosclerosis</i> 209:32. | 7. Mori, T. et al. (1996) <i>Thromb. Haemost.</i> 75:49. |
| 2. Miyakis, S. et al. (2004) <i>Thromb. Res.</i> 114:335. | 8. Hunt, J. et al. (1993) <i>Proc. Natl. Acad. Sci.</i> 90:2141. |
| 3. Wurm, H. (1984) <i>Int. J. Biochem.</i> 16:511. | 9. Guerin, J. et al. (2002) <i>J. Biol. Chem.</i> 277:2644. |
| 4. Mehdi, H. et al. (1994) <i>J. Virol.</i> 68:2415. | 10. Sakai, T. et al. (2007) <i>Am. J. Pathol.</i> 171:1659. |
| 5. Castro, A. et al. (2010) <i>Atherosclerosis</i> 209:201. | 11. Adams, M. (2008) <i>Semin. Thromb. Haemost.</i> 34:251. |
| 6. Shi, T. et al. (2004) <i>Proc. Natl. Acad. Sci.</i> 101:3939. | 12. Jing, X. et al. (2010) <i>J. Cancer Res. Clin. Oncol.</i> 16:1671. |

Contact us



Global www.epotobiotech.com service@epotobiotech.com

China No.10 Xinghuo Road, Pukou District, Nanjing China

TEL:+86 18652072210